Logo image of ZOM

ZOMEDICA CORP (ZOM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:ZOM - CA98980M1095 - Common Stock

0.0973 USD
0 (-0.21%)
Last: 3/4/2025, 8:08:11 PM
Fundamental Rating

3

Overall ZOM gets a fundamental rating of 3 out of 10. We evaluated ZOM against 186 industry peers in the Health Care Equipment & Supplies industry. ZOM has a great financial health rating, but its profitability evaluates not so good. ZOM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZOM has reported negative net income.
ZOM had a negative operating cash flow in the past year.
ZOM had negative earnings in each of the past 5 years.
In the past 5 years ZOM always reported negative operating cash flow.
ZOM Yearly Net Income VS EBIT VS OCF VS FCFZOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of ZOM (-29.05%) is comparable to the rest of the industry.
ZOM has a Return On Equity (-30.66%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROIC N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ZOM Yearly ROA, ROE, ROICZOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 69.64%, ZOM is doing good in the industry, outperforming 79.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ZOM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZOM Yearly Profit, Operating, Gross MarginsZOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

More info and screens

8

2. Health

2.1 Basic Checks

ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZOM has about the same amount of shares outstanding.
Compared to 5 years ago, ZOM has more shares outstanding
ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZOM Yearly Shares OutstandingZOM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M
ZOM Yearly Total Debt VS Total AssetsZOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 3.68 indicates that ZOM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.68, ZOM is in the better half of the industry, outperforming 72.63% of the companies in the same industry.
There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.68
ROIC/WACCN/A
WACC8.9%
ZOM Yearly LT Debt VS Equity VS FCFZOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 10.82 indicates that ZOM has no problem at all paying its short term obligations.
ZOM has a better Current ratio (10.82) than 92.63% of its industry peers.
ZOM has a Quick Ratio of 10.15. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.
ZOM has a Quick ratio of 10.15. This is amongst the best in the industry. ZOM outperforms 92.63% of its industry peers.
Industry RankSector Rank
Current Ratio 10.82
Quick Ratio 10.15
ZOM Yearly Current Assets VS Current LiabilitesZOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ZOM have decreased strongly by -57.89% in the last year.
ZOM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.33%.
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%

3.2 Future

Based on estimates for the next years, ZOM will show a decrease in Earnings Per Share. The EPS will decrease by -7.13% on average per year.
ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.91% yearly.
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%

3.3 Evolution

ZOM Yearly Revenue VS EstimatesZOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ZOM Yearly EPS VS EstimatesZOM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZOM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZOM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZOM Price Earnings VS Forward Price EarningsZOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZOM Per share dataZOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

A cheap valuation may be justified as ZOM's earnings are expected to decrease with -5.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%

More info and screens

0

5. Dividend

5.1 Amount

ZOM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZOMEDICA CORP

NYSEARCA:ZOM (3/4/2025, 8:08:11 PM)

0.0973

0 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-07 2025-05-07
Inst Owners9.39%
Inst Owner Change-59.89%
Ins Owners0.74%
Ins Owner Change0%
Market Cap95.35M
Revenue(TTM)26.73M
Net Income(TTM)-62.19M
Analysts80
Price Target0.26 (167.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.83%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)-20.3%
Revenue beat(4)1
Avg Revenue beat(4)-17.04%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)3.78%
Revenue beat(8)1
Avg Revenue beat(8)-16.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-380%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.57
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.03
BVpS0.21
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.64%
FCFM N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.87%
Cap/Sales 25.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.82
Quick Ratio 10.15
Altman-Z 3.68
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)120.38%
Cap/Depr(5y)90.3%
Cap/Sales(3y)29.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%
EBIT growth 1Y-50.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-88.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70%
OCF growth 3YN/A
OCF growth 5YN/A

ZOMEDICA CORP / ZOM FAQ

Can you provide the ChartMill fundamental rating for ZOMEDICA CORP?

ChartMill assigns a fundamental rating of 3 / 10 to ZOM.


What is the valuation status for ZOM stock?

ChartMill assigns a valuation rating of 0 / 10 to ZOMEDICA CORP (ZOM). This can be considered as Overvalued.


How profitable is ZOMEDICA CORP (ZOM) stock?

ZOMEDICA CORP (ZOM) has a profitability rating of 1 / 10.


What is the expected EPS growth for ZOMEDICA CORP (ZOM) stock?

The Earnings per Share (EPS) of ZOMEDICA CORP (ZOM) is expected to decline by -110.78% in the next year.